

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Service, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188) Washington, DC 20503.

PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE (DD-MM-YYYY) 30-10-2007	2. REPORT TYPE Quarterly	3. DATES COVERED (From - To) Jul – Sep 2007		
4. TITLE AND SUBTITLE Quarterly Performance / Technical Report		5a. CONTRACT NUMBER N/A		
		5b. GRANT NUMBER N00014-05-1-0859		
		5c. PROGRAM ELEMENT NUMBER N/A		
6. AUTHOR(S) Setterholm, Michelle		5d. PROJECT NUMBER N/A		
		5e. TASK NUMBER Project 1, 2, 3, 4		
		5f. WORK UNIT NUMBER N/A		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) National Marrow Donor Program 3001 Broadway St., N.E., Ste. 500 Minneapolis, MN 55413		8. PERFORMING ORGANIZATION REPORT NUMBER N/A		
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Office of Naval Research 875 N. Randolph St. Arlington, VA 22203		10. SPONSOR/MONITOR'S ACRONYM(S) ONR		
		11. SPONSORING/MONITORING AGENCY REPORT NUMBER N/A		
12. DISTRIBUTION AVAILABILITY STATEMENT Approved for public release				
13. SUPPLEMENTARY NOTES N/A				
14. ABSTRACT <p>1. <u>Contingency Preparedness</u>: Collect information from transplant centers, build awareness of the Transplant Center Contingency Planning Committee and educate the transplant community about the critical importance of establishing a nationwide contingency response plan.</p> <p>2. <u>Rapid Identification of Matched Donors</u> : Increase operational efficiencies that accelerate the search process and increase patient access are key to preparedness in a contingency event.</p> <p>3. <u>Immunogenetic Studies</u>: Increase understanding of the immunologic factors important in HSC transplantation.</p> <p>4. <u>Clinical Research in Transplantation</u>: Create a platform that facilitates multicenter collaboration and data management.</p>				
15. SUBJECT TERMS Research in HLA Typing, Hematopoietic Stem Cell Transplantation and Clinical Studies to Improve Outcomes				
16. SECURITY CLASSIFICATION OF: a. REPORT U		17. LIMITATION OF ABSTRACT Same as Report	18. NUMBER OF PAGES 9	19a. NAME OF RESPONSIBLE PERSON Dennis L. Confer, MD – Chief Medical Officer
				19b. TELEPHONE NUMBER (Include area code) 612.362.3425

Grant Award N00014-05-1-0859

QUARTERLY
PERFORMANCE / TECHNICAL REPORT
FOR
JULY 1, 2007 to SEPTEMBER 30, 2007

Office of Naval Research
And

The National Marrow Donor Program
3001 Broadway Street N.E.
Minneapolis, MN 55413
1-800-526-7809

20071101395

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 1, 2007 through September 30, 2007

TABLE OF CONTENTS

TASK	DESCRIPTION	STATUS	PAGE
IIA.1.1	Secure Interest of Transplant Physicians	Open	3
IIA.1.2	GCSF in Radiation Exposure	Closed	4
IIA.1.3	Patient Assessment Guidelines	Closed	4
IIA.1.4	National Data Collection Model	Closed	4
IIA.2.1	Contingency Response Network	Open	4
IIA.2.2	Standard Operating Procedures	Closed	4
IIA.3.1	Information Technology Infrastructure	Closed	4
IIB.1.1	Resolution Speeds Donor Selection	Closed	5
IIB.1.2	Evaluate HLA-DRB1 High Resolution Typing	Closed	5
IIB.1.3	Evaluate HLA-C Typing of Donors	Open	5
IIB.1.4	Evaluate Buccal Swabs	Closed	5
IIB.2.1	Collection of Primary Data	Closed	5
IIB.2.2	Validation of Logic of Primary Data	Closed	5
IIB.2.3	Reinterpretation of Primary Data	Closed	5
IIB.2.4	Genotype Lists & Matching algorithm	Closed	5
IIB.3.1	Phase I of EM Haplotype Logic	Closed	5
IIB.3.2	Enhancement of EM Algorithm	Closed	5
IIB.3.3	Optimal Registry Size Analysis	Closed	5
IIB.3.4	Target Underrepresented Phenotypes	Closed	5
IIB.3.5	Bioinformatics Web Site	Closed	5
IIB.3.6	Consultants to Improve Algorithm	Open	6
IIB.4.1	Expand Network Communications	Closed	6
IIB.4.2	Central Contingency Management	Closed	6
IIC.1.1	Donor Recipient Pair Project	Closed	6
IIC.2.1	Analysis of non-HLA Loci	Closed	7
IIC.2.2	Related Pairs Research Repository	Closed	7
IID.1.1	Observational Research, Clinical Trials and NIH Transplant Center	Open	7
IID.1.2	Research with NMDP Donors	Closed	7
IID.1.3	Expand Immunobiology Research	Closed	7
	Acronym List		8

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 1, 2007 through September 30, 2007

II.A. Contingency Preparedness – Hypothesis 1: Recovery of casualties with significant myelosuppression following radiation or chemical exposure is optimal when care plans are designed and implemented by transplant physicians

Aim A.1.1: Secure Interest of Transplant Physicians	Period 8 Activity: Funding provided by both 0859 and 0704 contracts this quarter:
	<ul style="list-style-type: none"> • Conducted physician education seminar titled: <u>Medical and Organizational Challenges Resulting from a Radiological/Nuclear Emergency Seminar Radiological/Nuclear Emergency.</u> <ul style="list-style-type: none"> ○ Seminar was held on September 25, 2007 in Bethesda, MD. ○ The Medical College of Wisconsin provided 6 CME credits for attendees ○ 132 people advance registered to attend, and 17 people registered the day of the seminar ○ Topics and key speakers include: <ul style="list-style-type: none"> ■ Threat Assessment : Brooke Buddemeier, C.H.P. - Lawrence Livermore National Laboratory ■ A Possible Scenario for Nuclear Casualties: Carl Curling, Sc.D. - Institute for Defense Analysis ■ Lessons from the Past: Chernobyl: Alla Shapiro, M.D. - Food and Drug Administration ■ Mass Casualty Event Case Studies: <ul style="list-style-type: none"> • David Rutstein, M.D. - Health and Human Services • Nelson Valverde, M.D. - State University of Rio de Janeiro ■ Introduction to Radiation Biology: Michael Robbins, Ph.D. - Wake Forest University School of Medicine ■ Biodosimetry: Albert Wiley, M.D. - REACTS & WHO Collaborating Center at Oak Ridge ■ ARS Skin syndrome: Viktor Meienke, M.D. - Bundeswehr Institute of Radiobiology ■ ARS Hematologic syndrome: Theodor Fliedner, M.D. - Ulm University ■ ARS Gastrointestinal syndrome: Martin Hauer-Jensen, M.D. - University of Arkansas for Medical Sciences ■ Radiation-induced Brain Injury: Michael Robbins, Ph.D. - Wake Forest University School of Medicine ■ Multi-organ Failure : Marc Benderitter, M.D. - Institut De Radioprotection et de Surete Nucléaire

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 1, 2007 through September 30, 2007

		<ul style="list-style-type: none"> ▪ National Response Process - the HHS "Playbook": C. Norman Coleman, M.D. - ▪ National Institute of Health ▪ New Approaches to Therapy Next Generation Medical Countermeasures: Nelson Chao, M.D. - Duke University
Aim A.1.2: GCSF in Radiation Exposure		Period 8 Activity: This task is closed.
Aim A.1.3: Patient Assessment Guidelines		Period 8 Activity: This task is closed.
Aim A.1.4: National Data Collection Model		Period 8 Activity: This task is closed.
		II.A. Contingency Preparedness – Hypothesis 2: Coordination of the care of casualties who will require hematopoietic support will be essential in a contingency situation.
Aim A.2.1: Contingency Response Network		Period 8 Activity: Funding provided by both 0859 and 0704 grants this quarter: RITN development: <ul style="list-style-type: none"> • Completed the signing of 53 centers to participate in RITN: <ul style="list-style-type: none"> ○ 37 transplant centers ○ 9 donor centers ○ 7 cord blood banks
Aim A.2.2: Sibling Typing Standard Operating Procedures		Period 8 Activity: This task is closed.
		II.A. Contingency Preparedness – Hypothesis 3: NMDP's critical information technology infrastructure must remain operational during contingency situations that directly affect the Coordinating Center.
Aim A.3.1: I.S. Disaster Recovery / Business Continuity Planning		Period 8 Activity: This task is closed.

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 1, 2007 through September 30, 2007

II.B. Rapid Identification of Matched Donors – Hypothesis 1: Increasing the resolution and quality of the HLA testing of volunteers on the registry will speed donor selection.	
Aim B.1.1: Increase Registry Diversity	Period 8 Activity: This task is closed.
Aim B.1.2: Evaluate HLA-DRB1 High Res typing	Period 8 Activity: This task is closed.
Aim B.1.3: Evaluate HLA-C Typing of Donors	Period 8 Activity: Impact of HLA-C typing on HR/CT/WU rates and time to transplant <ul style="list-style-type: none">Abstract accepted for ASHI 2007 annual meeting.Final report in progress.
Aim B.1.4: Evaluate Buccal Swabs	Period 8 Activity: This task is closed.
II.B. Rapid Identification of Matched Donors – Hypothesis 2: Primary DNA typing data can be used within the registry to improve the quality and resolution of volunteer donor HLA assignments.	
Aim B.2.1: Collection of Primary Data	Period 8 Activity: This task is closed.
Aim B.2.2: Validation of Logic of Primary Data	Period 8 Activity: This task is closed.
Aim B.2.3: Reinterpretation of Primary Data	Period 8 Activity: This task is closed.
Aim B.2.4: Genotype Lists & Matching Algorithm	Period 8 Activity: This task is closed.
II.B. Rapid Identification of Matched Donors – Hypothesis 3: Registry data on HLA allele and haplotype frequencies and on the nuances of HLA typing can be used to design computer algorithms to predict the best matched donor.	
Aim B.3.1: Phase I of EM Haplotype Logic	Period 8 Activity: This task is closed.
Aim B.3.2: Enhancement of EM Algorithm	Period 8 Activity: This task is closed.
Aim B.3.3: Optimal Registry Size Analysis	Period 8 Activity: This task is closed.
Aim B.3.4: Target Under-represented Phenotypes	Period 8 Activity: This task is closed.
Aim B.3.5: Bioinformatics Web Site	Period 8 Activity: This task is closed.

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 1, 2007 through September 30, 2007

Aim B.3.6: Maximize software using consultant data**Period 8 Activity:**

An informational PI meeting was held at NMDP for the internal and external reviewers involved in the Search Strategy Advice program. Updates included: operational efficiencies, new research data, standardized report format, new haplotype/allele data, cord blood matching (single and double cords) information, introduction of Hapologic II, Antigen Recognition Site matching and new applications (HaploStats and MatchView).

The NMDP HLA Search Strategy Advisors provided 409 search strategy reviews to 87 transplant centers during the quarter. External advisors wrote 256 search reviews for 70 centers with an average turnaround time of 4.4 days. Internal advisors completed 153 reports for 58 centers with a turnaround time average of 2.6 days. Average turnaround time for all 409 reviews was 3.7 days.

II.B. Rapid Identification of Matched Donors – Hypothesis 4: Reducing the time and effort required to identify closely matched donors for patients in urgent need of HSC transplants will improve access to transplantation and patient survival in the context of a contingency response and routine patient care.

Aim B.4.1: Expand Network Communications **Period 8 Activity:** This task is closed.

Aim B.4.2: Central Contingency Management **Period 8 Activity:** This task is closed.

II.C. Immunoogenetic Studies – Hypothesis 1: HLA mismatches may differ in their impact on transplant outcome, therefore, it is important to identify and quantify the influence of specific HLA mismatches. In contingency situations it will not be possible to delay transplant until a perfectly matched donor can be found.

Aim C.1.1: Donor Recipient Pair Project **Period 8 Activity:** This task is closed.

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 1, 2007 through September 30, 2007

II.C. Immunogetic Studies - Hypothesis 2: Even when patient and donor are HLA matched, GVHD occurs so other loci may play a role.	
Aim C.2.1: Analysis of non-HLA loci	Period 8 Activity: This task is closed.
Aim C.2.2: Related Pairs Research Repository	Period 8 Activity: This task is closed.
II.D. Clinical Research in Transplantation – Hypothesis 1: Clinical research in transplantation improves transplant outcomes and supports preparedness for a contingency response.	
Aim D.1.1: Observational Research, Clinical Trials and NIH Transplant Center	<p>Period 8 Activity:</p> <ul style="list-style-type: none"> Renal Cell Carcinoma trial accrual status; 13 total screened since initiation of trial, 1 remains in screening stage, 2 enrolled and transplanted. One patient did die of disease progression which was determined to be unrelated to study participation. Adult Double Cord trial officially opened on August 8th. At the end of this quarter a total of 3 sites are open for enrollment. Sites currently identifying potential patients. At the end of this quarter 332 patient/donor pairs were enrolled in the PBSC vs Marrow trial. Enrollment and work-ups continue to be strong. Staff continues to work on various observational studies. CIBMTR submitted 18 abstracts to the ASH meetings of which 2 were from the Immunobiology Working Committee and 4 from the GVHD
Aim D.1.2: Research with NMDP Donors	Period 8 Activity: This task is closed.
Aim D.1.3: Expand Immunobiology Research	Period 8 Activity: This task is closed.

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 1, 2007 through September 30, 2007

ACRONYM LIST

AABB	American Association of Blood Banks	ICRHIER	International Consortium for Research on Health Effects of Radiation
AML	Acute Myelogenous Leukemia	IS	Information Services
ARS	Acute Radiation Syndrome (also known as Acute Radiation Sickness)	IT	Information Technology
ASBMT	American Society for Blood and Marrow Transplantation	IRB	Institutional Review Board
ASHI	American Society for Histocompatibility and Immunogenetics	KIR	Killer Immunoglobulin-like Receptor
B-LCLs	B-Lymphoblastoid Cell Lines	NCI	National Cancer Institute
BMT CTN	Blood and Marrow Transplant - Clinical Trials Network	MHC	Major Histocompatibility Complex
C&A	Certification and Accreditation	MICA	MHC Class I-Like Molecule, Chain A
CBMTG	Canadian Blood and Marrow Transplant Group	MICB	MHC Class I-Like Molecule, Chain B
CBB	Cord Blood Bank	MUD	Matched Unrelated Donor
CBC	Congressional Black Caucus	NCBM	National Conference of Black Mayors
CBS	Canadian Blood Service	NIH	National Institutes of Health
CBU	Cord Blood Unit	NIMS	National Incident Management System
CHTC	Certified Hematopoietic Transplant Coordinator	NK	Natural Killer
CBMTR	Center for International Blood & Marrow Transplant Research	NMDP	National Marrow Donor Program
CLIA	Clinical Laboratory Improvement Amendment	NRP	National Response Plan
CME	Continuing Medical Education	NST	Non-myeloablative Allogeneic Stem Cell Transplantation
CREG	Cross Reactive Groups	OCR/ICR	Optical Character Recognition/Intelligent Character Recognition
CT	Confirmatory Testing	OIT	Office of Information Technology
CTA	Clinical Trial Application	OMB	Office of Management and Budget
DIY	Do it yourself	ONR	Office of Naval Research
DKMS	Deutsche Knochenmarkspenderdatei	PBMC	Peripheral Blood Mononuclear Cells

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 1, 2007 through September 30, 2007

DMSO	Dimethylsulphoxide	PBSC	Peripheral Blood Stem Cell
DNA	Deoxyribonucleic Acid	PCR	Polymerase Chain Reaction
D/R	Donor/Recipient	PSA	Public Service Announcement
EBMT	European Group for Blood and Marrow Transplantation	QC	Quality control
EM	Expectation Maximization	RCC	Renal Cell Carcinoma
EMDIS	European Marrow Donor Information System	REAC/TS	Radiation Emergency Assistance Center/Training Site
FBI	Federal Bureau of Investigation	RFP	Request for Proposal
FDA	Food and Drug Administration	RFQ	Request for Quotation
Fst	Fixation Index	RITN	Radiation Injury Treatment Network
GETS	Government Emergency Telecommunications Service	SBT	Sequence Based Typing
GCSF	Granulocyte-Colony Stimulating Factor (also known as filgrastim)	SCTOD	Stem Cell Therapeutics Outcome Database
GvHD	Graft vs Host Disease	SG	Sample Group
HHS	Health and Human Services	SSP	Sequence Specific Primers
HIPAA	Health Insurance Portability and Accountability Act	SSOP	Sequence Specific Oligonucleotide Probes
HLA	Human Leukocyte Antigen	STAR®	Search, Tracking and Registry
HML	Histoimmunogenetics Mark-up Language	TC	Transplant Center
HR	High Resolution	TED	Transplant Essential Data
HRSA	Health Resources and Services Administration	TNC	Total Nucleated Cell
HSC	Hematopoietic Stem Cell	TSA	Transportation Security Agency
IBWC	Immunobiology Working Committee	URD	Unrelated Donor
IDM	Infectious Disease Markers	WMDA	World Marrow Donor Association
IHWG	International Histocompatibility Working Group	WU	Work-up
IND	Investigational New Drug		